Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-134-7 | CAS number: 1304-76-3
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Oral absorption: The assumption appears justified that upon oral uptake the systemic uptake is low for bismuth. An oral absorption factor of 1% will be taken forward for risk characterisation purposes as a conservative assumption.
Inhalation absorption: Considering the very low oral bioavailability and the minimal predicted deposition in the respiratory tract, it is proposed to take forward an inhalation absorption factor of 1% for the purpose of risk characterisation, thus rendering corrections when extrapolating route-to-route (oral-inhalation) unnecessary.
Key value for chemical safety assessment
Additional information
Oral absorption
There are some publications that allow an assessment of the oral bioavailability of bismuth metal in rats, which are however somewhat of age. Information from two review articles(Slikkerveer, A.; de Wolff, F.A. (1989) and Tillman, L.A.; et al. (1996)) that were considered to contain relevant and reliable data are summarised.
For details please refer to the endpoint summary for toxicokinetics, metabolism and distribution.
Inhalation absorption
No data on inhalation absorption and distribution are available for bismuth metal or bismuth compounds.
Nevertheless, after completion of a testing programme on dustiness testing and particle size analysis of the airborne fraction on commercially available forms of bismuth metal powder, dibismuth trioxide and bismuth (III) trinitrate pentahydrate, the collected information can be used to estimate inhalation absorption factors based on a prediction of deposition patterns in the respiratory tract (MPPD model), in accordance with guidance developed under HERAG.
For details please refer to the endpoint summary for toxicokinetics, metabolism and distribution.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
